Price Chart

Profile

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
URL https://www.argenx.com
Investor Relations URL https://us.argenx.com/investors
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Oct. 31, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
URL https://www.argenx.com
Investor Relations URL https://us.argenx.com/investors
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Oct. 31, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A